Patents by Inventor Cosme Ordonez-Garcia

Cosme Ordonez-Garcia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CEA binding agents and compositions to reverse CEA-mediated tumorigenic effects on human cancer cells, restore sensitivity to drug induced apoptosis and uses thereof
    Publication number: 20060051352
    Abstract: The present invention relates to differentiation, apoptosis and tumorigenicity. The present invention more particularly relates to compositions comprising ligands which target CEA such that the adhesion, differentiation-Inhibitory and apoptosis-resistance activities (tumorigenic effects) of Ig superfamily member, CEA, can be reduced or blocked. More particularly, the present invention relates to CEA-binding agents comprising compositions which reverse the CEA-mediated tumorigenic effects and enable a lowering of the doses of a chemotherapeutic agent. In one embodiment the invention relates to methods of reducing, preventing or reversing CEA-mediated tumorigenic effects comprising a use of an amount of a CEA declustering agent comprising compositions that can reverse a CEA mediated tumorigenic effect.
    Type: Application
    Filed: April 4, 2005
    Publication date: March 9, 2006
    Inventors: Clifford Stanners, Christian Ilantzis, Cosme Ordonez-Garcia
  • Antibodies and cyclic peptides which bind CEA (carcinoembryonic antigens) and their use as cancer therapeutics
    Publication number: 20060024314
    Abstract: The present invention relates to differentiation and tumorigenicity. The present invention more particularly relates to ligands which target CEA and CEACAM6 such that the adhesion, differentiation-Inhibitory activities and tumorigenic effects of Ig superfamily members, CEA and CEACAM6, can be reduced or blocked. More particularly, the present invention relates to CEA-binding agents which reverse CEA-mediated tumorigenic effects by declustering CEA and CEACAM6. In one embodiment the invention relates to methods of reducing, preventing or reversing a CEA-mediated tumorigenic effect comprising a use of a CEA-mediated tumorigenic effect reducing CEA-declustering agent. In one embodiment, the invention relates to compositions and use thereof for reversing CEA-mediated tumorigenic effects on human cancer cells and uses thereof.
    Type: Application
    Filed: April 4, 2005
    Publication date: February 2, 2006
    Inventors: Clifford Stanners, Christian Ilantzis, Cosme Ordonez-Garcia, Maryam Taheri, Robert Screaton, Abraham Fuks, H. Saragovi
  • CEA/NCA-based differentiation cancer therapy
    Publication number: 20050153375
    Abstract: The present invention relates to a novel cancer therapy based on interference with the function or on downregulation of overproduced CEA/NCA, which plays an instrumental role in tumorigenesis and malignant progression through its differentiation-blocking activity. More precisely, there is provided three short amino acid sequence subdomains in the N domain of CEA and NCA that, when applied as peptides, peptide mimetics or anti-sudomain monoclonal antibodies to malignant tumors overproducing CEA/NCA, induce them to differentiate, thereby inhibiting their ability to grow and increasing the efficacy of other modes of treatment. Four other means of releasing the CEA/NCA-imposed differentiation block are also provided.
    Type: Application
    Filed: January 25, 2005
    Publication date: July 14, 2005
    Inventors: Clifford Stanners, Christian Ilantzis, Cosme Ordonez-Garcia, Maryam Taheri, Robert Screaton, Abraham Fuks, H.U. Saragovi